The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).
 
Richard T. Lee
Other Relationship - Grow Ohio Pharmaceuticals
 
Ravi Kumar Paluri
No Relationships to Disclose
 
Kabir Mody
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; FibroGen; MedImmune; Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma
 
Brian Simpson
Employment - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
Research Funding - Tricon Pharmaceuticals
Travel, Accommodations, Expenses - Tricon Pharmaceuticals
 
Bonne J. Adams
Employment - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
 
Charles P. Theuer
Employment - Tricon Pharmaceuticals
Leadership - Tricon Pharmaceuticals
Stock and Other Ownership Interests - Tricon Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Tricon Pharmaceuticals
 
Ahmed Omar Kaseb
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Consulting or Advisory Role - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Research Funding - Bayer/Onyx; Bristol-Myers Squibb; Genentech; Merck
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck